Aptose Biosciences Inc. announced that clinical data for tuspetinib, a once daily oral therapy, has been selected for oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, CA. Lead investigator Naval Daver, MD, Professor, Director Leukemia Research Alliance Program, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, will present data from Aptose's ongoing APTIVATE trial of tuspetinib in relapsed/refractory patients with acute myeloid leukemia.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.68 CAD | -0.59% | +2.44% | -49.85% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-49.85% | 19.33M | |
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- APS Stock
- News Aptose Biosciences Inc.
- Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting